Market Place
Sourcing Support
Nexalin Progresses FDA Alzheimer`s Strategy Post Key Leadership
15 Apr 2026 //
GLOBENEWSWIRE
Nexalin Hosts Live Investor Webinar On April 21
14 Apr 2026 //
GLOBENEWSWIRE
Nexalin Participates in and Commends Recent Momentum Supporting
23 Feb 2026 //
GLOBENEWSWIRE
Nexalin Technology Receives Nasdaq Listing Status Notification
23 Jan 2026 //
GLOBENEWSWIRE
Study Shows Nexalin`s DIFS Neurostimulation Enhances Attention
14 Jan 2026 //
GLOBENEWSWIRE
Nexalin Technology Hosts Live Investor Webinar On December 4
02 Dec 2025 //
GLOBENEWSWIRE
Nexalin Technology Appoints Carmi Masha As Exclusive Distributor
13 Nov 2025 //
GLOBENEWSWIRE
Nexalin Gen-2 Sync Q-Submission Accepted By FDA For Alzheimer
05 Nov 2025 //
GLOBENEWSWIRE
Nexalin Tech To Attend 2025 Maxim Growth Summit
10 Oct 2025 //
GLOBENEWSWIRE
Nexalin Technology Names Justin Van Fleet Cfo for Growth Phase
01 Aug 2025 //
GLOBENEWSWIRE
Nexalin Reforms Scientific Board to Advance Alzheimer’s Program
13 May 2025 //
GLOBENEWSWIRE
Nexalin Technology Closes $5.0M Public Offering
06 May 2025 //
GLOBENEWSWIRE
Nexalin Technology Prices $5.0M Public Offering of Common Stock
05 May 2025 //
GLOBENEWSWIRE
Nexalin Technology Starts FDA Q-Submission for Gen-2 SYNC
01 May 2025 //
GLOBENEWSWIRE
Nexalin Completes Phases One-Five for HALO Clinical Research
23 Apr 2025 //
GLOBENEWSWIRE
Nexalin Technology Secures USPTO Patent for DIFS Technology
14 Apr 2025 //
GLOBENEWSWIRE
Nexalin Technology`s Live Investor Webinar & Q&A on April 3
26 Mar 2025 //
GLOBENEWSWIRE
Nexalin Tech Gets USPTO Nod For DIFS Tech In Substance Use
03 Mar 2025 //
GLOBENEWSWIRE
Nexalin Begins Patient Recruitment For TBI & PTSD Study
28 Feb 2025 //
GLOBENEWSWIRE
Nexalin Technology Welcomes Gen. Wesley Clark to Advisory Board
26 Feb 2025 //
GLOBENEWSWIRE
Nexalin gets UCSD IRB Approval for HALO™for mTBI & PTSD
18 Feb 2025 //
GLOBENEWSWIRE
Nexalin Named Industry Co-Chair Of National TBI Coalition
10 Feb 2025 //
GLOBENEWSWIRE
Nexalin Technology Hosts Live Investor Webinar And Q&A Session
23 Jan 2025 //
GLOBENEWSWIRE
Nexalin CEO Shares 2025 Outlook, Highlights Recent Achievements
14 Jan 2025 //
GLOBENEWSWIRE
Nexalin Technology Completes Ph 1of its Innovative Virtual Clinic
23 Dec 2024 //
GLOBENEWSWIRE
Nexalin Technology CEO Letter to Shareholders
11 Nov 2024 //
GLOBENEWSWIRE
Nexalin Technology Regains Nasdaq Listing Compliance
01 Nov 2024 //
GLOBENEWSWIRE
Nexalin Technology Hosts Live Investor Webinar on Nov 5
01 Nov 2024 //
GLOBENEWSWIRE
Nexalin Technology Plans Clinical Trial With Gen-3 Halo Headset
22 Oct 2024 //
GLOBENEWSWIRE
Nexalin Technology Appoints Carolyn Shelton As Senior VP
14 Oct 2024 //
GLOBENEWSWIRE
Nexalin Participates In Roundtable On Virtual Opioid Treatment
05 Sep 2024 //
GLOBENEWSWIRE
Nexalin Joins Industry Coalition For Substance Use Recovery
18 Jul 2024 //
GLOBENEWSWIRE
Nexalin Technology Announces Closing of $5.2 Million Public Offering
01 Jul 2024 //
GLOBENEWSWIRE
Nexalin Technology Announces Pricing of $5.2 Million Public Offering
27 Jun 2024 //
GLOBENEWSWIRE
Nexalin Technology Announces Positive Clinical Study Data in MDD in Journal
26 Jun 2024 //
GLOBENEWSWIRE
Nexalin Tech Awarded Patent For Non-Invasive Device For Alzheimer’s And Dementia
20 Jun 2024 //
GLOBENEWSWIRE
Nexalin Announces Approval to Sell Nexalin’s Neurostimulation Device by Anvisa
13 Jun 2024 //
GLOBENEWSWIRE
Nexalin Tech: Presenting At Spring MicroCap Rodeo On June 6
04 Jun 2024 //
GLOBENEWSWIRE
FDA Aligns On Nexalin`s HALO Anxiety, Insomnia Clinical Study Design
03 Jun 2024 //
GLOBENEWSWIRE
Nexalin Joins TBI Registry Coalition For Awareness, Research
22 May 2024 //
GLOBENEWSWIRE
Nexalin Live Investor Webinar And Q&A On May 23
09 May 2024 //
GLOBENEWSWIRE
Nexalin Technology Regains Compliance with Nasdaq Continued Listing Requirements
25 Apr 2024 //
GLOBENEWSWIRE
Nexalin Technology CEO Provides Letter to Shareholders
10 Apr 2024 //
GLOBENEWSWIRE
Nexalin Technology Accelerates HALOClarity Production
09 Apr 2024 //
GLOBENEWSWIRE
Nexalin Tech Awarded Key Patent Related to its Gen-3 HALO Clarity a Non-Invasive
04 Apr 2024 //
GLOBENEWSWIRE
Nexalin Announces the Appointment of Government Affairs Veteran William
02 Apr 2024 //
GLOBENEWSWIRE
Nexalin Announces Positive Results of Gen-2 tACS Device for Reducing Pain
28 Mar 2024 //
GLOBENEWSWIRE
Nexalin Technology Commences Sales of Gen-2 Neurostimulation Device
14 Mar 2024 //
GLOBENEWSWIRE
Nexalin Technology Announces Poster Presentation
13 Mar 2024 //
GLOBENEWSWIRE
Nexalin Announces Positive Results from Study of its Gen-2 tACS Device
06 Mar 2024 //
GLOBENEWSWIRE
Nexalin Announces Regulatory Approval in Oman for Gen-2 Neurostimulation Device
08 Feb 2024 //
GLOBENEWSWIRE
Nexalin Awarded Key Patent Related to its Deep-Brain Stimulation Device
23 Jan 2024 //
GLOBENEWSWIRE
Nexalin Technology Unveils Next-Generation HALO„¢ Clarity
11 Jan 2024 //
GLOBENEWSWIRE
Nexalin Reports Results of Study Supporting Therapeutic Benefits of Gen-2
18 Dec 2023 //
GLOBENEWSWIRE
Nexalin Announces Formation of New Military & Government Advisory Board
25 Oct 2023 //
GLOBENEWSWIRE
Nexalin Announces Publication of Groundbreaking Deep-Brain Stimulation Study
16 Oct 2023 //
GLOBENEWSWIRE
Nexalin Reports Results of Study Supporting Therapeutic Benefits of its Gen-2
07 Aug 2023 //
GLOBENEWSWIRE
Nexalin Announces Public Sector Division to Capitalize on Opportunities to Serve U.S. Government Agencies
26 Jul 2023 //
GLOBENEWSWIRE
Nexalin Technology and Wider Come Limited Announce Joint Venture Agreement
01 Jun 2023 //
GLOBENEWSWIRE
Nexalin Technology Provides 2022 Year-End Business Update
27 Mar 2023 //
GLOBENEWSWIRE
